Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABUS NASDAQ:CGEM NASDAQ:CNTX NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.66+0.3%$4.37$3.04▼$5.10$919.54M0.622.02 million shs2.21 million shsCGEMCullinan Therapeutics$15.80+2.2%$14.23$5.68▼$16.74$971.22M-0.09816,517 shs957,207 shsCNTXContext Therapeutics$3.02+14.8%$2.53$0.49▼$3.62$278.03M1.571.29 million shs645,390 shsPHATPhathom Pharmaceuticals$10.91-1.7%$11.72$3.92▼$18.31$870.14M0.571.19 million shs610,474 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+6.67%+10.48%+10.48%+0.87%+44.10%CGEMCullinan Therapeutics+11.71%+9.03%+16.94%+7.66%+97.95%CNTXContext Therapeutics+1.15%+21.20%+16.37%+8.23%+279.56%PHATPhathom Pharmaceuticals-2.03%-2.63%-5.13%-9.90%+176.12%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABUSArbutus Biopharma$4.66+0.3%$4.37$3.04▼$5.10$919.54M0.622.02 million shs2.21 million shsCGEMCullinan Therapeutics$15.80+2.2%$14.23$5.68▼$16.74$971.22M-0.09816,517 shs957,207 shsCNTXContext Therapeutics$3.02+14.8%$2.53$0.49▼$3.62$278.03M1.571.29 million shs645,390 shsPHATPhathom Pharmaceuticals$10.91-1.7%$11.72$3.92▼$18.31$870.14M0.571.19 million shs610,474 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABUSArbutus Biopharma+6.67%+10.48%+10.48%+0.87%+44.10%CGEMCullinan Therapeutics+11.71%+9.03%+16.94%+7.66%+97.95%CNTXContext Therapeutics+1.15%+21.20%+16.37%+8.23%+279.56%PHATPhathom Pharmaceuticals-2.03%-2.63%-5.13%-9.90%+176.12%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABUSArbutus Biopharma 2.00Hold$5.006.72% UpsideCGEMCullinan Therapeutics 2.67Moderate Buy$30.7598.67% UpsideCNTXContext Therapeutics 2.88Moderate Buy$6.60119.49% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.00128.81% UpsideCurrent Analyst Ratings BreakdownLatest CNTX, CGEM, ABUS, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.005/8/2026CGEMCullinan Therapeutics WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$36.00 ➝ $37.005/4/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$38.004/28/2026CGEMCullinan Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.004/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ABUSArbutus Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CNTXContext Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/10/2026CGEMCullinan Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026PHATPhathom Pharmaceuticals BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$16.00 ➝ $18.003/24/2026CNTXContext Therapeutics D. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABUSArbutus Biopharma$191.45M4.83N/AN/A$1.32 per share3.55CGEMCullinan TherapeuticsN/AN/AN/AN/A$5.96 per shareN/ACNTXContext TherapeuticsN/AN/AN/AN/A$0.57 per shareN/APHATPhathom Pharmaceuticals$204.89M4.25N/AN/A($4.22) per share-2.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABUSArbutus Biopharma-$33.50M$0.835.64N/AN/A83.95%129.32%112.24%8/5/2026 (Estimated)CGEMCullinan Therapeutics-$219.88M-$3.36N/AN/AN/AN/A-51.45%-47.64%8/6/2026 (Estimated)CNTXContext Therapeutics-$36.12M-$0.42N/AN/AN/AN/A-59.95%-54.78%8/5/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.00N/A-76.77%N/A-44.29%8/6/2026 (Estimated)Latest CNTX, CGEM, ABUS, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ABUSArbutus Biopharma-$0.03$0.87+$0.90$0.87$0.75 million$179.13 million5/7/2026Q1 2026CGEMCullinan Therapeutics-$0.8359-$0.75+$0.0859-$0.75$3.67 millionN/A5/6/2026Q1 2026CNTXContext Therapeutics-$0.12-$0.09+$0.03-$0.09N/AN/A3/31/2026Q4 2025ABUSArbutus BiopharmaN/A$0.87N/A$0.87N/A$179.13 million3/23/2026Q4 2025CNTXContext Therapeutics-$0.11-$0.14-$0.03-$0.14N/AN/A3/20/2026Q4 2025ABUSArbutus Biopharma-$0.0550-$0.01+$0.0450-$0.01$0.83 million$1.05 million3/10/2026Q4 2025CGEMCullinan Therapeutics-$0.80-$0.77+$0.03-$0.77$5.56 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABUSArbutus BiopharmaN/AN/AN/AN/AN/ACGEMCullinan TherapeuticsN/AN/AN/AN/AN/ACNTXContext TherapeuticsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABUSArbutus BiopharmaN/A54.2654.26CGEMCullinan TherapeuticsN/A10.2810.28CNTXContext TherapeuticsN/A8.968.96PHATPhathom PharmaceuticalsN/A2.212.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABUSArbutus Biopharma43.79%CGEMCullinan Therapeutics86.31%CNTXContext Therapeutics14.03%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipABUSArbutus Biopharma19.90%CGEMCullinan Therapeutics8.60%CNTXContext Therapeutics4.80%PHATPhathom Pharmaceuticals9.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABUSArbutus Biopharma90197.54 million158.23 millionOptionableCGEMCullinan Therapeutics3061.46 million56.17 millionOptionableCNTXContext Therapeutics791.88 million87.47 millionNot OptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableCNTX, CGEM, ABUS, and PHAT HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals (PHAT) Receives a Buy from BarclaysMay 24 at 12:47 AM | theglobeandmail.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 22, 2026 | globenewswire.comPhathom Pharmaceuticals Inc Ordinary shares PHATMay 21, 2026 | morningstar.comMPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual MeetingMay 20, 2026 | globenewswire.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 6.78%May 17, 2026 | aaii.comAPhathom Pharmaceuticals Signals Strong Growth on Earnings CallMay 16, 2026 | theglobeandmail.comPhathom Pharmaceuticals Announces $130 Million Public OfferingMay 12, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 9, 2026 | marketbeat.comPhathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineMay 5, 2026 | finance.yahoo.comHow The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksMay 5, 2026 | finance.yahoo.com147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.May 3, 2026 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)May 2, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)May 2, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 2, 2026 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?May 1, 2026 | marketbeat.comPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingMay 1, 2026 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPSApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings MissApril 30, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTX, CGEM, ABUS, and PHAT Company DescriptionsArbutus Biopharma NASDAQ:ABUS$4.66 +0.02 (+0.32%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.Cullinan Therapeutics NASDAQ:CGEM$15.80 +0.34 (+2.20%) As of 02:48 PM Eastern This is a fair market value price provided by Massive. Learn more.Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.Context Therapeutics NASDAQ:CNTX$3.02 +0.39 (+14.83%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.Phathom Pharmaceuticals NASDAQ:PHAT$10.91 -0.19 (-1.71%) As of 02:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case Zscaler Stock Drops 30%: Why the Dip Is a Buy Opportunity Shake Shack Insiders Buy as SHAK Stock Faces More Pressure Rocket Lab Keeps Making Headlines and Highs—Here's What's Driving the Latest Move Record Revenue, Rising Dividends—So Why Aren't Analysts Saying Buy? Qualcomm's TikTok AI Chip Deal Rewrites the Rules Micron’s $1 Trillion Memory Melt-Up Keysight: The AI and Defense Stock Seeing Big Price Target Boosts Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
